You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BRAF V600E mutation positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Dabrafenib Plus Trametinib In Rare BRAF V600E Mutation-Positive

Not yet recruiting
  • Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
  • Non-investigational
  • (no location specified)
May 11, 2023

Colorectal Cancer, BRAF V600E Mutation Positive Trial (Encorafenib Oral Capsule + Cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • BRAF V600E Mutation Positive
  • Encorafenib Oral Capsule + Cetuximab
  • (no location specified)
Jan 30, 2023

BRAF V600E Mutation Trial run by the NHGRI (Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide)

Completed
Has Results
  • BRAF V600E Mutation
  • Dabrafenib Mesylate
  • Trametinib Dimethyl Sulfoxide
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 6, 2021

NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +32 more
  • (no location specified)
Mar 30, 2023

NSCLC Trial in China (Dabrafenib, Trametinib)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Harbin, Heilongjiang, China
  • +9 more
Jun 13, 2022

Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV Trial in Chicago

Recruiting
  • Stage IV Colorectal Cancer Positive for BRAF V600E Mutation
  • +2 more
  • Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
  • Chicago, Illinois
    Northwestern University
Nov 16, 2022

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID

Active, not recruiting
  • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Metastatic Colorectal Cancer, BRAF V600E Mutation Positive Trial in France (Collection of blood samples)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • BRAF V600E Mutation Positive
  • Collection of blood samples
  • Avignon, France
  • +26 more
Nov 25, 2022

First Line Treatment for BRAFV600E Mutant Metastatic Colorectal

Completed
  • BRAF V600E Mutation Positive
  • Metastatic Colorectal Cancer
  • Non Interventional study
  • St. Veit/Glan, Austria
  • +33 more
Jan 20, 2023

Cancer Trial in Worldwide (Dabrafenib, Trametinib)

Completed
Has Results
  • Cancer
  • Los Angeles, California
  • +49 more
Apr 1, 2022

Thyroid Carcinoma, Thyroid Cancer, Thyroid Cancer, Follicular Trial in United States (I-124 PET/CT lesion dosimetry,

Recruiting
  • Thyroid Carcinoma
  • +5 more
  • I-124 PET/CT lesion dosimetry
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Mar 3, 2022

Cancer Trial (Dabrafenib, Trametinib)

Not yet recruiting
  • Cancer
  • (no location specified)
May 25, 2023

Metastatic Melanoma Trial in Darlinghurst, Sydney, Brisbane (Palliative radiotherapy, Dabrafenib and trametinib (combination))

Completed
  • Metastatic Melanoma
  • Palliative radiotherapy
  • Dabrafenib and trametinib (combination)
  • Darlinghurst, New South Wales, Australia
  • +2 more
Apr 6, 2022

Non Small Cell Lung Cancer Trial (HLX208+HLX10)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • HLX208+HLX10
  • (no location specified)
Nov 30, 2022

Aspirin in Combination With Trametinib and Dabrafenib

Not yet recruiting
  • NSCLC
  • +4 more
  • Combind asprin with Trametinib and Dabrafenib
  • (no location specified)
Aug 4, 2023

BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer

Recruiting
  • Metastatic Non-small Cell Lung Cancer
  • BRAF V600 Mutation
    • Lyon, Rhône Alpes, France
      CHU Lyon - Hôpital Cardio-Vasculaire et Pneumologique Louis Prad
    Sep 14, 2022

    Melanoma Trial in Worldwide (encorafenib, binimetinib, pembrolizumab)

    Recruiting
    • Melanoma
    • Siena, Toscana, Italy
    • +11 more
    Jun 23, 2023

    Colorectal Cancer, Colon Cancer, BRAF V600E Trial (Binimetinib)

    Not yet recruiting
    • Colorectal Cancer
    • +4 more
    • (no location specified)
    Aug 18, 2022

    Metastatic Colorectal Cancer, mCRC Trial in Shenyang (HLX208)

    Recruiting
    • Metastatic Colorectal Cancer
    • mCRC
    • Shenyang, Liaoning, China
      Liaoning Cancer Hospital
    May 1, 2022

    NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)

    Not yet recruiting
    • NSCLC
    • +2 more
    • Guangzhou, Guangdong, China
      Cancer Center of Sun-Yat Sen University
    Sep 19, 2023

    CRC Trial in Shanghai (HLX208, Cetuximab Injection [Erbitux])

    Recruiting
    • CRC
    • HLX208
    • Cetuximab Injection [Erbitux]
    • Shanghai, China
      Fudan University Affiliated Oncology Hospital
    Dec 30, 2021

    Melanoma Trial in Beijing (HL-085, Vemurafenib)

    Recruiting
    • Melanoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Apr 10, 2022

    Melanoma Metastatic, BRAF V600 Mutation Trial in Italy (Experimental combination beyond Focal Progression, Pembrolizumab or

    Active, not recruiting
    • Melanoma Metastatic
    • BRAF V600 Mutation
    • Experimental combination beyond Focal Progression
    • Pembrolizumab or Nivolumab
    • Bari, BA, Italy
    • +13 more
    Dec 1, 2021

    BRAF V600-mutated Lung Carcinoma Treated With Combination of

    Completed
    • Non Small Cell Lung Cancer
    • BRAF V600 Mutation
      • Créteil, France
      • +1 more
      Jun 29, 2022

      BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma Trial in Guangzhou (Encorafenib)

      Completed
      • BRAF V600E Unresectable or Metastatic Melanoma
      • +2 more
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      Jun 9, 2022